EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain

Jessica R Allegretti, Krisztina B Gecse, Michael V Chiorean, Marjorie Argollo, Xiang Guo iD, Nervin Lawendy, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Leonardo Salese, Peter M Irving

Journal of Gastroenterology and Hepatology · 2024-02 · 39 (2) · 264-271

DOI: 10.1111/jgh.16386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 12.11.2023. Verfasst von Jessica R Allegretti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Piperidines, Pyrimidines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis. These post hoc analyses evaluated early improvement in patient‐reported outcomes with tofacitinib 10 mg twice daily (BID) in OCTAVE Open among patients with ulcerative colitis who experienced treatment failure with placebo (retreatment subpopulation) or tofacitinib 5 mg BID (dose escalation subpopulation) during maintenance.

Methods

Endpoints based on Mayo subscores (rectal bleeding improvement, stool frequency improvement, and symptomatic [both rectal bleeding and stool frequency] improvement) were analyzed overall and by prior tumor necrosis factor inhibitor (TNFi) failure status from month (M)1–M6 in OCTAVE Open. Changes from baseline in partial Mayo score, rectal bleeding subscore, and stool frequency subscore at M1 were also analyzed, by M2 clinical response status.

Results

At M1 of OCTAVE Open, 83.2%, 70.3%, and 64.4% of patients in the retreatment subpopulation ( n = 101) had rectal bleeding improvement, stool frequency improvement, and symptomatic improvement, respectively. Corresponding values in the dose escalation subpopulation ( n = 57) were 59.6%, 50.9%, and 38.6%. For both subpopulations, results were generally consistent regardless of prior TNFi failure. In the dose escalation subpopulation, mean decrease from baseline in partial Mayo score and stool frequency subscore at M1 was greater in patients with versus without a clinical response at M2.

Conclusions

Rectal bleeding improvement and stool frequency improvement were achieved by M1 in many patients receiving tofacitinib 10 mg BID in both subpopulations, with no apparent difference by prior TNFi failure. Analyses were limited by small sample sizes for some subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePiperidinesPyrimidinesHumansRemission InductionDrug TaperingTreatment InterruptionTreatment Outcome

Stichwörter der Autor:innen

colitispatient-reported outcome measurestofacitinibulcerative

Substanzen

tofacitinibPiperidinesPyrimidines

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Swedish Medical Center, Seattle, Washington, USA.
  • Department of Gastroenterology, Federal University of São Paulo, São Paulo, Brazil.
  • Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Pfizer Inc, New York, New York, USA.

ORCID-Profile: Xiang Guo

Förderung

  • Pfizer

Zitieren

APA

Allegretti, J. R., Gecse, K. B., Chiorean, M. V., Argollo, M., Guo, X., Lawendy, N., Su, C., Mundayat, R., Paulissen, J., Salese, L., & Irving, P. M. (2024). Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. Journal of Gastroenterology and Hepatology, 39(2), 264-271. https://doi.org/10.1111/jgh.16386

Vancouver

Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, et al. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. Journal of Gastroenterology and Hepatology. 2024;39(2):264-271. doi:10.1111/jgh.16386

BibTeX
@article{Allegretti2024,
  author = {Allegretti, Jessica R and Gecse, Krisztina B and Chiorean, Michael V and Argollo, Marjorie and Guo, Xiang and Lawendy, Nervin and Su, Chinyu and Mundayat, Rajiv and Paulissen, Jerome and Salese, Leonardo and Irving, Peter M},
  title = {Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  volume = {39},
  number = {2},
  pages = {264--271},
  doi = {10.1111/jgh.16386}
}
Kostenlos starten →